Adam Boyd Vaughn, | |
620 Skyline Dr, Jackson, TN 38301-3923 | |
(731) 541-5000 | |
Not Available |
Full Name | Adam Boyd Vaughn |
---|---|
Gender | Male |
Speciality | Anesthesiology - Critical Care Medicine |
Location | 620 Skyline Dr, Jackson, Tennessee |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003515271 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
207LC0200X | Anesthesiology - Critical Care Medicine | 5572 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Adam Boyd Vaughn, 16 Woodwinds Cv, Jackson, TN 38305-7407 Ph: () - | Adam Boyd Vaughn, 620 Skyline Dr, Jackson, TN 38301-3923 Ph: (731) 541-5000 |
News Archive
The Substance and Mental Health Services Administration (SAMHSA) is issuing a heat advisory to alert the nation to the increased risk of heat-related illnesses for individuals with mental and substance use disorders. Children and older adults with these conditions are particularly vulnerable to elevated temperatures.
Listening to the lawyers talking nonstop last week about health care gave me a headache, so I decided to consult one of the nation's top doctors. He offered a real-world diagnosis of what's happening in health care -; and a reminder of how much it's changing, regardless of what the Supreme Court decides about Obamacare. My medical guru is Delos "Toby" Cosgrove, chief executive of Cleveland Clinic, a $6 billion network that's one of the biggest and best providers in the country.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
Researchers have discovered a new compound that restores the health of mice infected with methicillin-resistant Staphylococcus aureus (MRSA), an otherwise dangerous bacterial infection. The new compound targets an enzyme not found in human cells but which is essential to bacterial survival.
› Verified 2 days ago